Antineoplaston Therapy in Treating Patients With Newly-diagnosed Glioblastoma Multiforme

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically or cytologically confirmed Glioblastoma Multiforme
• •Subtotal resection or biopsy only of tumor
• •Measurable tumor by MRI scan performed within two weeks prior to study entry
• •Tumor must be at least 5 mm
• •No brain stem tumor
• •PATIENT CHARACTERISTICS:
• •Age:
• •18 and over
• •Performance status:
• •Karnofsky 60-100%
• •Life expectancy:
• •More than 4 months
• •Hematopoietic:
• •WBC at least 1,500/mm\^3
• •Platelet count at least 50,000/mm\^3
• •Hemoglobin at least 10 g/dL
• •Hepatic:
• •No hepatic failure
• •Bilirubin no greater than 2.5 mg/dL
• •SGOT and SGPT no greater than 5 times upper limit of normal
• •Renal:
• •Creatinine no greater than 2.5 mg/dL
• •No history of renal conditions that would contraindicate high dosages of sodium
• •Cardiovascular:
• •No uncontrolled hypertension
• •Other:
• •Not pregnant or nursing
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy:
• •No prior immunotherapy
• •No concurrent immunomodulatory agents
• •Chemotherapy:
• •No prior chemotherapy
• •No concurrent antineoplastic agents
• •Endocrine therapy:
• •Concurrent corticosteroids for cerebral edema allowed
• •Radiotherapy:
• •No prior radiotherapy
• •Surgery:
• •See Disease Characteristics
• •Recovered from any prior surgery